Who Owns Dexilant?

Dexilant is manufactured under Takeda's corporate sustainability framework. Takeda has established science-based targets for greenhouse gas emissions reduction consistent with limiting global temperature rise to 1.5 degrees Celsius, as recognized by the Science Based Targets initiative in 2020. The company has been included in the Dow Jones Sustainability Asia Pacific Index for multiple consecutive years.

Takeda's quality laboratory in Singapore, which supports testing and quality assurance for products including Dexilant, achieved the highest level of green lab certification from My Green Lab. The company has also received WorldStar Global Packaging Awards from the World Packaging Organization for pioneering use of bio-polyethylene in pharmaceutical packaging materials.

Takeda maintains ethical marketing and sales compliance programs governing the promotion of Dexilant. The company states that all marketing activities adhere to regulatory requirements and ethical standards in pharmaceutical marketing. However, the pay-for-delay antitrust lawsuits (described below) have raised questions about Takeda's business practices related to Dexilant.

Takeda's sustainability disclosures are at the corporate level and do not separately report environmental metrics specific to Dexilant manufacturing. The company publishes an annual integrated report covering environmental, social, and governance performance.

Dexilant itself has not received independent pharmaceutical industry awards. Recognition related to the product comes through Takeda's corporate-level achievements.

Takeda has been included in the Dow Jones Sustainability Asia Pacific Index for multiple consecutive years through 2022, reflecting the company's environmental, social, and governance performance. The company was also included on CDP's 2022 A list for climate change leadership and transparency.

Takeda received two WorldStar Global Packaging Awards from the World Packaging Organization for pioneering use of bio-polyethylene in pharmaceutical primary and secondary packaging. These packaging innovations apply across Takeda's product portfolio, including gastroenterology medications.

Takeda's quality laboratory in Singapore achieved the highest level of green lab certification from My Green Lab, representing leadership in sustainable laboratory practices that support pharmaceutical quality assurance across Takeda's product lines.

The FDA approval of Dexilant for adolescent patients aged 12 to 17 in 2016 expanded the drug's eligible patient population and represented a regulatory milestone for the product. However, this was a regulatory approval rather than an award.

Dexilant has not been subject to major product safety recalls. However, the drug has been at the center of significant legal and regulatory controversies.

Pay-for-delay antitrust lawsuits: In March 2025, major retailers including Walgreens, Kroger, Albertsons, and H-E-B filed a federal antitrust lawsuit in California accusing Takeda and TWi Pharmaceuticals of conspiring to delay the release of a generic version of Dexilant. The retailers alleged that Takeda paid TWi to delay generic market entry until January 2022, despite patent expirations that would have allowed generic entry as early as June 2020. The lawsuit claims this arrangement forced retailers and consumers to pay higher prices for brand-name Dexilant for approximately 18 months beyond when generic competition should have begun.

CVS antitrust lawsuit: In September 2025, CVS filed a similar antitrust complaint against Takeda and TWi Pharmaceuticals. CVS alleged that the reverse payment arrangement increased its expenses in purchasing Dexilant for customers and prevented competition from other generic drug manufacturers even after Takeda's patent protection had expired.

Court ruling: In February 2026, a federal court ruled that Takeda and TWi Pharmaceuticals must face most of the proposed antitrust class action, allowing the lawsuit to proceed. The court denied Takeda's motion to dismiss the case, finding sufficient evidence to support the plaintiffs' claims of an anticompetitive pay-for-delay agreement.

PPI product liability claims: As of March 31, 2024, more than 6,100 product liability lawsuits related to the use of Prevacid and Dexilant had been filed against Takeda in US federal and state courts. The cases were consolidated in a multi-district litigation (MDL) in federal court in New Jersey. Plaintiffs alleged they developed kidney injuries or gastric cancer as a result of taking Prevacid and/or Dexilant. Takeda disclosed these lawsuits in its FY2024 financial report. The company has not publicly disclosed the resolution status of all these cases.

Regulatory scrutiny of PPIs: The proton pump inhibitor drug class, which includes Dexilant, has faced increased regulatory and medical scrutiny regarding long-term use risks. Studies have associated long-term PPI use with potential kidney-related conditions (including chronic kidney disease and acute interstitial nephritis), stroke risks, bone fractures, vitamin B12 deficiency, and Clostridioides difficile infections. The FDA has issued safety communications regarding these risks. These concerns have led to increased scrutiny of PPI prescribing practices but have not resulted in a recall of Dexilant.

Takeda Actos settlement: While not directly related to Dexilant, Takeda's $2.4 billion settlement in 2014 over thousands of lawsuits related to its diabetes drug Actos (pioglitazone), which was associated with increased bladder cancer risk, has been noted as part of the company's broader legal history. This settlement does not involve Dexilant but is part of Takeda's corporate litigation record.